摘要
GLP-1受体激动剂凭借出色的减肥疗效及多适应证释放的积极数据引起全球关注。当前诺和诺德和礼来占据GLP-1市场近90%的份额,两者分别凭借司美格鲁肽和替尔泊肽两大明星产品垄断GLP-1减肥市场,且两者蓄力角逐减肥市场动作不断。在全球超十亿肥胖人口的市场容量下,大批追随者涌入GLP-1赛道。多靶点、口服、长效、多适应证、联合用药,为药企提升竞争力的五大突破口。当前,GLP-1减肥药临床布局密集,多项临床进入末期,面临的安全性、成本效益、依从性等瓶颈仍有待进一步突破。
GLP-1 receptor agonists have attracted global attention due to their excellent weight loss efficacy and positive data released from multiple indications.Currently,Novo Nordisk and Eli Lilly hold nearly 90%of the GLP-1 market share,monopoly of the GLP-1 weight loss market with two star products,Smegglutide and Telposide,respectively,and the both competition the weight loss market with continuously actions.With a global market capacity of over one billion obese people,a large number of followers flock to the GLP-1 track.Multi-targets,oral,long term efficacy,multiple indications,combination therapy are five breakthroughs for pharmaceutical enterprises to enhance competitiveness.The current clinical layout of GLP-1 weight loss drugs is dense,and multiple clinical trials are in the final stage.the bottlenecks faced in terms of security,cost-effectiveness,and compliance need to be further broken through.
作者
杨四娟
YANG Sijuan(Shanghai Library(Institute of Scientific&Technical Information of Shanghai),Shanghai 200031,China)
出处
《竞争情报》
2024年第3期55-63,共9页
Competitive Intelligence
